Solstice, a New York City-based technology firm, secured $21 million in Series A funding to scale its AI-native platform designed to accelerate pharmaceutical commercialisation. The financing round, announced on 28 May 2026, was led by Transformation Capital with participation from existing seed investors Twelve Below and Virtue Ventures. Other backers of the company include Ford Street Ventures, Go Global Ventures, and Cory Capital.
The capital injection brings Solstice’s total funding to approximately $25 million since its public launch in 2025. Co-founders Aris Saxena and Yiwen Li developed the platform to address the Medical, Legal, and Regulatory (MLR) review process, a critical compliance bottleneck that often stalls life sciences marketing campaigns for up to three months. The company intends to use the new funds to accelerate product engineering and expand its go-to-market and customer success teams.
For biopharmaceutical brands, the cost of these delays is high, as the global market is projected to exceed $100 billion in drug sales this year. Traditional manual workflows often require three months and at least three review cycles to move a single marketing asset from creation to approval. Because drug patent exclusivity windows are rigid, every day spent in regulatory review represents a loss of potential revenue and delayed patient access to therapies.
Engineering a clinical grounding engine for pharma compliance
The Solstice platform operates as a specialised “appliance” for the biopharma industry, moving away from general-purpose generative AI. It ingests a brand’s specific clinical trial data, FDA documentation, and approved literature to ensure all marketing claims are grounded in fact. This focus on precision is vital because Ijeoma Eti addresses overlooked AI infrastructure faults and security concerns that can arise when unregulated models produce “hallucinations” or non-compliant content.
The system automatically queries drafted medical claims against clinical literature, fact-checking for regulatory risks before the content reaches human reviewers. Solstice reports that early corporate users have eliminated up to 84% of operational inefficiencies by automating the manual mapping of sentences to specific pages in clinical reports. The AI engine also scores assets on their likelihood of MLR approval, acting as a technical filter that ensures only high-quality drafts proceed through the pipeline.
Unifying content and performance feedback loops
The software integrates content creation, medical review, and performance analytics into a single workflow. It allows marketing teams to produce programmatic ads, digital campaigns, and communications for healthcare providers that are technically accurate from the first draft. This replaces fragmented processes where creative agencies and regulatory teams often work in silos, leading to excessive revisions.
Beyond creation, the system measures which compliant assets are successfully driving action from physicians and patients. This enables the platform to predict high-performing content types and generate targeted iterations. Such industrial-scale efficiency mirrors broader market trends, as seen when industrial and engineering stocks rally following breakthroughs in operational throughput and automated systems.
Compressing approval timelines from months to days
According to CEO Aris Saxena, the platform’s impact on speed-to-market is already measurable across its client base, which includes several of the top 20 global pharmaceutical brands. “Our customers used to run three review cycles per asset; now they run one or two at most,” Saxena stated. He noted that content that traditionally took months to clear can now be released in 10 days, representing a twelve-fold increase in campaign launch speeds.
The platform also enables teams to move from initial content creation to MLR submission in under 48 hours. This agility is particularly significant in crowded therapeutic areas like oncology and immunology, where brand differentiation depends on the ability to communicate new data quickly. By reducing the reliance on traditional agency models, Solstice allows labels to compete more effectively within shrinking patent windows.
As Solstice scales, the combination of AI-native technology and in-house subject-matter expertise aims to turn the platform into a standard operating system for life sciences commercialisation. For engineering and operations professionals, the development signals a transition toward a data-driven production line for pharmaceutical information, ensuring that compliance no longer serves as a barrier to industrial productivity.
By bridging the gap between clinical data and public health messaging, the firm is attempting to modernise a multi-billion dollar sector that has largely relied on paper-heavy legacy workflows.
